PUBLISHER: The Business Research Company | PRODUCT CODE: 1720801
PUBLISHER: The Business Research Company | PRODUCT CODE: 1720801
Gliosarcoma Global Market Report 2025
Gliosarcoma is a rare and aggressive brain tumor composed of both glial and sarcomatous tissue, primarily occurring in the cerebral hemisphere. It is studied to understand tumor biology and develop treatment strategies for glioblastoma and other brain malignancies.
The primary diagnostic methods for gliosarcoma include imaging techniques, histopathological examination, and biomarker testing. Imaging techniques, such as MRI, CT, and PET scans, are non-invasive methods used to visualize internal structures and detect abnormalities. Treatment options include surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy, with end users including hospitals, cancer research institutes, and specialty clinics.
The gliosarcoma market research report is one of a series of new reports from The Business Research Company that provides gliosarcoma market statistics, including gliosarcoma industry global market size, regional shares, competitors with a gliosarcoma market share, detailed gliosarcoma market segments, market trends and opportunities, and any further data you may need to thrive in the gliosarcoma industry. This gliosarcoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The gliosarcoma market size has grown strongly in recent years. It will grow from $1.19 billion in 2024 to $1.25 billion in 2025 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period was driven by increasing healthcare expenditure, a rising number of clinical trials, a growing global aging population, a higher prevalence of comorbidities such as diabetes and hypertension, and expanded healthcare insurance coverage.
The gliosarcoma market size is expected to see strong growth in the next few years. It will grow to $1.54 billion in 2029 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period is expected to be driven by the increasing incidence of gliosarcoma, rising awareness of brain cancers, growth in research funding for brain cancer, increasing demand for personalized treatments, and the expansion of healthcare infrastructure. Key trends include advancements in diagnostic techniques, the development of targeted therapies, the availability of advanced imaging technologies, innovations in surgical techniques, and technological advancements in drug delivery systems.
The rising incidence of brain tumors is expected to drive growth in the gliosarcoma market. A brain tumor is an abnormal growth of cells in the brain, which can be either benign or malignant and may cause symptoms such as headaches, seizures, and vision problems. The increasing number of brain tumor cases is attributed to improved diagnostic technologies, heightened awareness, and environmental and lifestyle factors that may contribute to greater exposure to risk factors. Gliosarcoma treatment plays a crucial role in managing this aggressive and rare cancer, aiming to alleviate symptoms, extend survival, and enhance the patient's quality of life. For example, in October 2022, the National Library of Medicine, a US-based biomedical library operated by the United States federal government, reported that in 2023, the United States recorded 94,390 new cases of brain and central nervous system (CNS) tumors, up from 93,470 cases in 2022. Malignant cases increased from 26,670 to 26,940, while non-malignant cases rose from 66,800 to 67,440. The growing incidence of brain tumors is thus fueling demand for gliosarcoma treatment.
Leading companies in the gliosarcoma market are focusing on developing advanced wearable technology to enhance cancer treatment and monitoring. Wearable devices are electronic gadgets worn on the body that track and analyze health data, offering real-time insights and improving patient engagement. For instance, in November 2024, Novocure Ltd., a UK-based oncology company, received U.S. Food and Drug Administration (FDA) approval for the use of Head Flexible Electrode (HFE) transducer arrays alongside Optune Gio for treating adult patients with glioblastoma multiforme (GBM). Optune Gio is a portable, wearable device that uses non-invasive arrays to deliver tumor-treating fields (TTFields), which apply physical forces to electrically charged components of dividing cancer cells, disrupting their rapid growth. The newly introduced HFE arrays are 50% thinner and one-third lighter than the ceramic discs used in the existing Optune Gio arrays, as they are made from a flexible polymer material, enhancing patient comfort and usability.
In October 2024, Merck & Co. Inc., a US-based pharmaceutical company, acquired Modifi Biosciences in a $1.3 billion deal. This acquisition strengthens Merck's oncology portfolio by advancing innovative therapies for glioblastoma and other cancers, further expanding its expertise in cancer treatment. Modifi Biosciences, based in the U.S., specializes in developing treatments for glioblastoma, reinforcing Merck's commitment to addressing complex oncological challenges.
Major players in the gliosarcoma market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma, Bio-Rad Laboratories Inc., Carl Zeiss AG, Elekta AB, Novocure Ltd., ImmunityBio Inc., Immatics Biotechnologies, Karyopharm Therapeutics Inc., Celon Laboratories Pvt. Ltd., Komipharm International Co. Ltd., Kintara Therapeutics Inc., Aveta Biomics Inc., Vigeo Therapeutics Inc.
North America was the largest region in the gliosarcoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gliosarcoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the gliosarcoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The gliosarcoma market consists of revenues earned by entities by providing services such as molecular diagnostics, clinical trials and research, palliative care services, rehabilitation, and recovery support. The market value includes the value of related goods sold by the service provider or included within the service offering. The gliosarcoma market also includes sales of diagnostic kits, research reagents, and patient monitoring devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Gliosarcoma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on gliosarcoma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for gliosarcoma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gliosarcoma market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Diagnosis Method: Imaging Techniques; Histopathological Examination; Biomarker Testing
- 2) By Treatment Type: Surgery; Radiation Therapy; Chemotherapy; Targeted Therapy; Immunotherapy
- 3) By End-User: Hospitals; Cancer Research Institutes; Specialty Clinics
- Subsegments:
- 1) By Imaging Techniques: Magnetic Resonance Imaging (MRI); Computed Tomography (CT) Scan; Positron Emission Tomography (PET) Scan
- 2) By Histopathological Examination: Hematoxylin and Eosin (H&E) Staining; Immunohistochemistry (IHC); Electron Microscopy
- 3) By Biomarker Testing: IDH Mutation Testing; MGMT Promoter Methylation Testing; ATRX Mutation Testing; TP53 Mutation Analysis
- Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.; Bayer AG
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Gliosarcoma Market Characteristics
3. Gliosarcoma Market Trends And Strategies
4. Gliosarcoma Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Gliosarcoma Growth Analysis And Strategic Analysis Framework
- 5.1. Global Gliosarcoma PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Gliosarcoma Market Growth Rate Analysis
- 5.4. Global Gliosarcoma Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Gliosarcoma Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Gliosarcoma Total Addressable Market (TAM)
6. Gliosarcoma Market Segmentation
- 6.1. Global Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Imaging Techniques
- Histopathological Examination
- Biomarker Testing
- 6.2. Global Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Surgery
- Radiation Therapy
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- 6.3. Global Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Cancer Research Institutes
- Specialty Clinics
- 6.4. Global Gliosarcoma Market, Sub-Segmentation Of Imaging Techniques, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Magnetic Resonance Imaging (MRI)
- Computed Tomography (CT) Scan
- Positron Emission Tomography (PET) Scan
- 6.5. Global Gliosarcoma Market, Sub-Segmentation Of Histopathological Examination, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hematoxylin and Eosin (H&E) Staining
- Immunohistochemistry (IHC)
- Electron Microscopy
- 6.6. Global Gliosarcoma Market, Sub-Segmentation Of Biomarker Testing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- IDH Mutation Testing
- MGMT Promoter Methylation Testing
- ATRX Mutation Testing
- TP53 Mutation Analysis
7. Gliosarcoma Market Regional And Country Analysis
- 7.1. Global Gliosarcoma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Gliosarcoma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Gliosarcoma Market
- 8.1. Asia-Pacific Gliosarcoma Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Gliosarcoma Market
- 9.1. China Gliosarcoma Market Overview
- 9.2. China Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Gliosarcoma Market
- 10.1. India Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Gliosarcoma Market
- 11.1. Japan Gliosarcoma Market Overview
- 11.2. Japan Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Gliosarcoma Market
- 12.1. Australia Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Gliosarcoma Market
- 13.1. Indonesia Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Gliosarcoma Market
- 14.1. South Korea Gliosarcoma Market Overview
- 14.2. South Korea Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Gliosarcoma Market
- 15.1. Western Europe Gliosarcoma Market Overview
- 15.2. Western Europe Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Gliosarcoma Market
- 16.1. UK Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Gliosarcoma Market
- 17.1. Germany Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Gliosarcoma Market
- 18.1. France Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Gliosarcoma Market
- 19.1. Italy Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Gliosarcoma Market
- 20.1. Spain Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Gliosarcoma Market
- 21.1. Eastern Europe Gliosarcoma Market Overview
- 21.2. Eastern Europe Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Gliosarcoma Market
- 22.1. Russia Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Gliosarcoma Market
- 23.1. North America Gliosarcoma Market Overview
- 23.2. North America Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Gliosarcoma Market
- 24.1. USA Gliosarcoma Market Overview
- 24.2. USA Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Gliosarcoma Market
- 25.1. Canada Gliosarcoma Market Overview
- 25.2. Canada Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Gliosarcoma Market
- 26.1. South America Gliosarcoma Market Overview
- 26.2. South America Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Gliosarcoma Market
- 27.1. Brazil Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Gliosarcoma Market
- 28.1. Middle East Gliosarcoma Market Overview
- 28.2. Middle East Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Gliosarcoma Market
- 29.1. Africa Gliosarcoma Market Overview
- 29.2. Africa Gliosarcoma Market, Segmentation By Diagnosis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Gliosarcoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Gliosarcoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Gliosarcoma Market Competitive Landscape And Company Profiles
- 30.1. Gliosarcoma Market Competitive Landscape
- 30.2. Gliosarcoma Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
31. Gliosarcoma Market Other Major And Innovative Companies
- 31.1. Bristol-Myers Squibb Company
- 31.2. Novartis AG
- 31.3. Eli Lilly and Company
- 31.4. Amgen Inc.
- 31.5. Teva Pharmaceutical Industries Ltd.
- 31.6. Regeneron Pharmaceuticals Inc.
- 31.7. Sun Pharmaceutical Industries Ltd.
- 31.8. Sumitomo Dainippon Pharma
- 31.9. Bio-Rad Laboratories Inc.
- 31.10. Carl Zeiss AG
- 31.11. Elekta AB
- 31.12. Novocure Ltd.
- 31.13. ImmunityBio Inc.
- 31.14. Immatics Biotechnologies
- 31.15. Karyopharm Therapeutics Inc.
32. Global Gliosarcoma Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Gliosarcoma Market
34. Recent Developments In The Gliosarcoma Market
35. Gliosarcoma Market High Potential Countries, Segments and Strategies
- 35.1 Gliosarcoma Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Gliosarcoma Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Gliosarcoma Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
